Assembly Bio to present topline Phase 1a data for HDV entry inhibitor ABI-6250 at EASL 2026

Assembly Biosciences

ASMB

0.00

Assembly Biosciences scheduled topline interim Phase 1a results for ABI-6250, an oral hepatitis D virus entry inhibitor, for presentation at EASL Congress in Barcelona on May 27, 2026.
Data from randomized, blinded study in healthy participants showed the drug was safe and supported its expected drug-exposure profile.
Readouts also indicated pharmacodynamic activity consistent with the drug’s intended mechanism.
Program positioned to move directly into a Phase 2 study by year-end, with ABI-6250 described as only oral entry inhibitor in clinical development for chronic hepatitis D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130200PRIMZONEFULLFEED9718703) on May 13, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.